Annuncio • Jun 27

Johnson & Johnson Presents New IMAAVY Data at European Academy of Neurology 2026 Congress Reinforcing Sustained Disease Control in Generalized Myasthenia Gravis

Johnson & Johnson announced new data across 12 abstracts at the European Academy of Neurology 2026 Congress that offer additional insight into the use of IMAAVY (nipocalimab-aahu) throughout clinically relevant points in the generalized myasthenia gravis (gMG) treatment journey. The analyses include adults with anti-AChR or anti-MuSK antibody-positive gMG who were early in their disease course or had lower baseline symptom burden – providing insight into the potential importance of addressing pathogenic immunoglobulin G (IgG) early in disease progression where use of advanced therapies may be less common. Additional research to be shared include outcomes shortly after common infections, which are a known cause of disease exacerbations in gMG, and plans to address evidence gaps in use of IMAAVY during pregnancy. Post-hoc analyses from the pivotal Vivacity-MG3 study in adults with antibody positive gMG (spanning anti-AChR+ and anti-MuSK+) will be presented which provide new insights that could inform clinical care including: Patients early in their disease course (within five years of diagnosis) show improved outcomes: IMAAVY plus standard of care (SOC) showed greater reductions in MG-ADL scores versus placebo plus SOC (-4.9 vs. -2.7) at Week 24, with a greater proportion of patients receiving IMAAVY also achieving the stringent measure of sustained meaningful clinical improvement (MCI) for =20 weeks compared to placebo. IMAAVY is the only FcRn blocker evaluated to demonstrate sustained MCI over this duration in the double-blind phase of its pivotal study. Patients with lower baseline symptom burden sustain MCI: IMAAVY plus SOC decreased symptom severity and improved daily functioning at Week 24 versus placebo plus SOC (MG-ADL scores of -4.5 vs. -2.3). A greater proportion of patients receiving IMAAVY also achieved sustained MCI in this setting, adding further insights for healthcare professionals into the use of IMAAVY in patients with less severe disease. Patients maintain control after contracting common infections: In the IMAAVY arm, observed symptom improvements were maintained within two weeks after patients contracted common infections, providing data on the use of IMAAVY after periods when the likelihood of disease exacerbations is elevated. Safety and tolerability were consistent across all patients in the study and across other nipocalimab studies. The overall incidence of adverse events (AEs) was 84% in both the IMAAVY and the placebo arms and serious adverse events (SAEs) were 9% in the IMAAVY arm compared to 14% in the placebo arm. Ongoing evidence generation in gMG will also be highlighted, including: Innovative PETUNIA study design: PETUNIA is designed to generate real-world safety data on pregnancy, maternal, and infant outcomes following exposure to IMAAVY during pregnancy. By leveraging prospective and retrospective reports the study aims to capture more detailed information on outcomes in this setting, helping to expand the evidence base beyond the traditional post-marketing safety monitoring requirements and support clinical decision-making in an area where current evidence is limited. IMAAVY is approved for adult and pediatric patients (12 years of age and older) with anti-AChR or anti-MuSK antibody positive gMG by the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). IMAAVY, an immunoselective neonatal Fc receptor (FcRn) blocker, is designed to target and reduce pathogenic immunoglobulin G (IgG) autoantibodies associated with generalized myasthenia gravis (gMG). Post-hoc analyses from the pivotal Vivacity-MG3 study in adults with antibody positive gMG (spanning anti-AChR+ and anti-MuSK+) will be presented which provide new insights that could inform clinical care including: Patients early in their disease course (within five years of diagnosis) show improved outcomes: IMAAVY plus standard of care (SOC) showed greater reductions in MG-ADL scores versus placebo plus SOC (-4.9 vs. -2.7) at Week 24, with a greater proportion of patients receiving IMAAVY also achieving the stringent measure of sustained meaningful clinical improvement (MCI) for =20 weeks compared to placebo. IMAAVY is the only FcRn blocker evaluated to demonstrate sustained MCI over this duration in the double-blind phase of its pivotal study. Patients with lower baseline symptom burden sustain MCI: IMAAVY plus SOC decreased symptom severity and improved daily functioning at Week 24 versus placebo plus SOC (MG-ADL scores of -4.5 vs. -2.3). A greater proportion of patients receiving IMAAVY also achieved sustained MCI in this setting, adding further insights for healthcare professionals into the use of IMAAVY in patients with less severe disease. Patients maintain control after contracting common infections: In the IMAAVY arm, observed symptom improvements were maintained within two weeks after patients contracted common infections, providing data on the use of IMAAVY after periods when the likelihood of disease exacerbations is elevated. Safety and tolerability were consistent across all patients in the study and across other nipocalimab studies. The overall incidence of adverse events (AEs) was 84% in both the IMAAVY and the placebo arms and serious adverse events (SAEs) were 9% in the IMAAVY arm compared to 14% in the placebo arm. Ongoing evidence generation in gMG will also be highlighted, including: Innovative PETUNIA study design: PETUNIA is designed to generate real-world safety data on pregnancy, maternal, and infant outcomes following exposure to IMAAVY during pregnancy. By leveraging prospective and retrospective reports the study aims to capture more detailed information on outcomes in this setting, helping to expand the evidence base beyond the traditional post-marketing safety monitoring requirements and support clinical decision-making in an area where current evidence is limited. IMAAVY is approved for adult and pediatric patients (12 years of age and older) with anti-AChR or anti-MuSK antibody positive gMG by the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). IMAAVY is an immunoselective treatment designed to target, bind with high affinity, and block the neonatal Fc receptor (FcRn), reducing circulating immunoglobulin G (IgG) antibodies that drive disease while also preserving key immune functions. IMAAVY is currently approved for the treatment of generalized myasthenia gravis (gMG) in adults and pediatric patients 12 years of age and older who are anti-acetylcholine receptor (AChR) or anti-muscle-specific tyrosine kinase (MuSK) antibody positive. Nipocalimab is being investigated across three key segments in the autoantibody space including Rheumatologic diseases, Rare Autoantibody diseases, and Maternal Fetal diseases mediated by maternal alloantibodies, in which blockade of IgG binding to FcRn in the placenta is believed to limit transplacental transfer of maternal alloantibodies to the fetus.

Rendimento totale per gli azionisti	2.6%
Rendimento futuro dei dividendi	2.2%
Crescita dei dividendi	5.5%
Prossima data di pagamento dei dividendi	15 Sep 26
Data di stacco del dividendo	25 Aug 26
Dividendo per azione	n/a
Rapporto di remunerazione	60%

Segmento	Rendimento dei dividendi
Azienda (JNJ)	2.0%
Fondo del 25% del mercato (CA)	1.6%
Top 25% del mercato (CA)	5.4%
Media del settore (Pharmaceuticals)	1.9%
Analista previsionale (JNJ) (fino a 3 anni)	2.2%

Dati	Ultimo aggiornamento (ora UTC)
Analisi dell'azienda	2026/07/26 15:31
Prezzo dell'azione a fine giornata	2026/07/24 00:00
Utili	2026/06/28
Utili annuali	2025/12/28

Pacchetto	Dati	Tempistica	Esempio Fonte USA ^*
Dati finanziari della società	10 anni	Conto economico Rendiconto finanziario Bilancio	Modulo SEC 10-K Modulo SEC 10-Q
Stime di consenso degli analisti	+3 anni	Previsioni finanziarie Obiettivi di prezzo degli analisti	Rapporti di ricerca degli analisti Blue Matrix
Prezzi di mercato	30 anni	Prezzi delle azioni Dividendi, scissioni e azioni	Dati di mercato ICE Modulo SEC S-1
Proprietà	10 anni	Top azionisti Insider trading	Modulo 4 SEC Modulo 13D SEC
Gestione	10 anni	Team di leadership Consiglio di amministrazione	Modulo SEC 10-K Modulo SEC DEF 14A
Sviluppi principali	10 anni	Annunci aziendali	Modulo 8-K SEC

Analista	Istituzione
David Toung	Argus Research Company
Matthew Miksic	Barclays
Lee Hambright	Bernstein

Johnson & Johnson Dividendi e riacquisti

Criteri Dividendo verificati 5/6

Informazioni chiave

Aggiornamenti recenti su dividendi e riacquisti

Johnson & Johnson Raises Quarterly Dividend, Payable on June 9, 2026

Johnson & Johnson Announces Quarterly Dividend for First Quarter 2026, Payable on First Quarter of 2026

Johnson & Johnson Declares Dividend for the Fourth Quarter of 2025, Payable on December 9, 2025

Recent updates

Johnson & Johnson Announces Positive Topline Results from the Three-Arm Investigational Phase 3 Monumental-6 Study Evaluating TECVAYLI® (Teclistamab-Cqyv) + TALVEY® (Talquetamab-Tgvs)

Johnson & Johnson Receives FDA Market Authorization for Ottava Robotic Surgical System

Johnson & Johnson Raises Earnings Guidance for the Full Year 2026

Johnson & Johnson Receives Fda Approval for Dual Energy Thermocool Smarttouch Sf Platform

Johnson & Johnson Presents New IMAAVY Data at European Academy of Neurology 2026 Congress Reinforcing Sustained Disease Control in Generalized Myasthenia Gravis

Johnson & Johnson Innovative Medicine Presents Results From Phase 2/3 ENERGY Study Demonstrating IMAAVY (Nipocalimab-Aahu) Durable Hemoglobin Response and Rapid Onset of Effect in Warm Autoimmune Hemolytic Anemia

Johnson & Johnson Expands U.S. Availability of TECNIS PureSee IOL, an Advanced Lens Option for Cataract Surgeons and Patients

Johnson & Johnson Presents Comprehensive Results From Phase 2/3 ENERGY Study Demonstrating Statistically Significant Durable Hemoglobin Response With IMAAVY In Warm Autoimmune Hemolytic Anemia

Johnson & Johnson (NYSE:JNJ) entered into a definitive agreement to acquire Firefly Bio, Inc. for $1 billion.

Johnson & Johnson Presents New Data Reinforcing the Role of Nipocalimab in Lowering the Autoantibodies Driving Sjögren's Disease

Johnson & Johnson Announces Results from Final Analysis of Phase 3 Proteus Study Showing Investigational Use of Apalutamide Plus Hormone Therapy Significantly Improves Clinical Outcomes for Patients with High-Risk Localized or Locally Advanced Prostate Cancer

Johnson & Johnson Presents New Data For TECVAYLI Demonstrating Superior Progression-Free And Overall Survival In Multiple Myeloma

Johnson & Johnson Receives FDA Approval For Label Expansion Of TREMFYA To Include Inhibition Of Structural Joint Damage In Adults With Active Psoriatic Arthritis

Johnson & Johnson to Report Q2, 2026 Results on Jul 15, 2026

Sieben Alexander, P.A. Secures $10.2 Million Verdict for Twin Cities Family Against Cosmetic Talc Manufacturers Vi-Jon and Four Co-Defendants—Gold Bond, Merck (Dr. Scholl's), Johnson & Johnson, and Perrigo Co. of Tennessee

Johnson & Johnson Announces Global Launch Of Shockwave C2 Aero Coronary IVL Catheter

Johnson & Johnson Announces Positive Phase 3 Fuzion Study Results For Tremfya In Perianal Fistulizing Crohn’s Disease

Johnson & Johnson Shows Greatest Improvement Across Key Efficacy Outcomes for Caplyta (Lumateperone) Among Adjunctive Mdd Treatments in New Network Meta-Analysis

Johnson & Johnson Receives FDA Approval for CAPLYTA Supplemental New Drug Application with Robust New Data Supporting Reduced Risk of Relapse in Schizophrenia

Johnson & Johnson (NYSE:JNJ) has entered into a definitive agreement to acquire Atraverse Medical, Inc.

Johnson & Johnson Showcases CARTO-Powered Innovation, Including Debut of CARTOSOUND SONATA, to Advance Arrhythmia Care at HRS 2026

Johnson & Johnson Raises Quarterly Dividend, Payable on June 9, 2026

Johnson & Johnson Showcases New Clinical Data for TECNIS PureSee IoL at ASCRS 2026 Demonstrating Excellent Contrast Sensitivity and Extended Range of Vision

Johnson & Johnson Launches Varipulse Pro Platform in Europe

Johnson & Johnson Presents One-Year Results for Icotyde in Plaque Psoriasis

Johnson & Johnson Announces FDA Approval Of ICOTYDE™ (icotrokinra) For Plaque Psoriasis Treatment

Johnson & Johnson Highlights Promising First-In-Human Erda-Idrs Results In Intermediate-Risk Non-Muscle-Invasive Bladder Cancer

Johnson & Johnson, Annual General Meeting, Apr 23, 2026

Canada-Wide Talcum Powder Class Action Certified Against Johnson & Johnson

Johnson & Johnson Announces U.S. FDA Approval of TECVAYLI Plus DARZALEX FASPRO For Relapsed/Refractory Multiple Myeloma

Johnson & Johnson Therapy Nipocalimab Granted U.S. FDA Fast Track designation in systemic lupus erythematosus (SLE)

Johnson & Johnson Announces Preliminary Results From Phase 1b Study Of Pasritamig In Combination With Docetaxel In Advanced Prostate Cancer

Blackstone Life Sciences and Johnson & Johnson Announces A Co-Funding Agreement for Acute Myeloid Leukemia

Bayer Files Suit Against Johnson & Johnson (J&J) and Janssen Biotech, Inc

Johnson & Johnson Announces New Long-Term Data from the Quasar Long-Term Extension Study

Johnson & Johnson Reportedly Prepares to Sell Orthopedics Unit for over $20 Billion

Johnson & Johnson Receives U.S. FDA Breakthrough Therapy Designation for Patients with Advanced Head and Neck Cancer

Johnson & Johnson Announces the U.S. Food and Drug Administration Approves a New, Simplified Monthly Dosing Schedule

Philadelphia Jury Returns $250,000 Verdict Against Johnson & Johnson in Latest Baby Powder-Ovarian Cancer Trial

Johnson & Johnson Presents Early Outcomes from the OMNY-AF Pilot Study at 2026 AF Symposium

Johnson & Johnson Announces New Real World Head-To-Head Analysis Demonstrating That Patients with Metastatic Castration-sensitive Prostate Cancer (mCSPC) Initiating ERLEADA®

Johnson & Johnson Announces the U.S. Food and Drug Administration Approval for DARZALEX Faspro (Daratumumab and Hyaluronidase-Fihj) in Combination with Bortezomib, Lenalidomide and Dexamethasone (D-Vrd)

Johnson & Johnson Provides Sales Guidance for the Full Year of 2026

Is Johnson & Johnson A Dividend Stock, Or Something Else?

Johnson & Johnson Announces New Analysis of Phase 3 Data Which Found Caplyta®? (Lumateperone) in Combination with an Antibody

Johnson & Johnson Announces Positive Topline Results from the Investigational Phase 3 MajesTEC-9 Study of TECVAYLI (teclistamab-cqyv) Monotherapy

Johnson & Johnson Elevates Leadership in Depression with New Data At 2026 American College of Neuropsychopharmacology Annual Meeting

Johnson & Johnson Announces New Longer Follow-Up Results from the Investigational Phase 1b/2 OrigAMI-1 Study Evaluating amivantamab-vmjw

Johnson & Johnson Submits OTTAVA Robotic Surgical System to the U.S. Food and Drug Administration

Johnson & Johnson Announces Quarterly Dividend for First Quarter 2026, Payable on First Quarter of 2026

Johnson & Johnson (NYSE:JNJ) completed the acquisition of Halda Therapeutics OpCo, Inc.

Minnesota Jury Delivers $65.5 Million History-Making Verdict Against Johnson & Johnson

Los Angeles Jury Delivers $40 Million Verdict Against Johnson & Johnson in Talcum Powder Ovarian Cancer Trial

Johnson & Johnson Announces U.S. Food and Drug Administration Approval of RYBREVANT FASPRO

Johnson & Johnson to Report Q1, 2026 Results on Apr 14, 2026

Johnson & Johnson Announces U.S. Food and Drug Administration Approves AKEEGA as the First Precision Therapy for BRCA2-Mutated Metastatic Castration-sensitive Prostate Cancer with 54% Reduction in Disease Prostate Cancer with 54% reduction in Disease Prostate Cancer

Hagens Berman Sobol Shapiro LLP and Lowey Dannenberg, P.C. Announce Certification of a Class of Third Party Payors Who Purchased or Paid for Some or All of the Price of Stelara

Johnson & Johnson Announces Updated Results For CARVYKTI In Relapsed Or Refractory Multiple Myeloma

Johnson & Johnson's INLEXZO Delivers 74% Disease-Free Survival at One Year in Bcg-Unresponsive, High-Risk, Papillary-Only NMIBC

Johnson & Johnson (NYSE:JNJ) signed a definitive agreement to acquire Halda Therapeutics Opco, Inc. for $3.0 billion.

FDA Approves Darzalex Faspro for Adult Patients with High-Risk Smoldering Multiple Myeloma

Johnson & Johnson Announces U.S. Food and Drug Administration Approval of Caplyta (Lumateperone)

Johnson & Johnson Announces Week 28 Results from Phase 2b ANTHEM-UC Study of Icotrokinra

Johnson & Johnson Announces Findings from the Phase 2 Dahlias Study

Johnson & Johnson Announces New Long-Term Results from the Phase 3 ICONIC-TOTAL Studya Evaluating icotrokinra

TECVAYLI® plus DARZALEX FASPRO® Combination Regimen Significantly Improves Progression-Free Survival and Overall Survival Versus Standard of Care

Johnson & Johnson Declares Dividend for the Fourth Quarter of 2025, Payable on December 9, 2025

Johnson & Johnson Raises Earnings Guidance for 2025

Johnson & Johnson to Showcase New Clinical and Real-World Data on Major Depressive Disorder Portfolio At 2025 ECNP Congress

Johnson & Johnson Announces TREMFYA® (Guselkumab) Is First and Only Il-23 Inhibitor to Demonstrate Sustained Clinical and Endoscopic Outcomes with A Fully Subcutaneous Regimen Through 48 Weeks in Ulcerative Colitis

Johnson & Johnson Announces U.S. Food and Drug Administration Approves Tremfya®? (Guselkumab) for the Treatment of Pediatric Plaque Psoriasis and Active Psoriatic Arritis

Johnson & Johnson Announces U.S. Approval for Subcutaneous Indication in Adults with Ulcerative Colitis